Concordia Healthcare Corp. T.CXR.R

info on UK anti-competitive cases

[mingzhu]

old cases .If CXR is involved then it would have been known now.


The UK OFT issues statement of objections to four pharma companies alleging they acted to delay effective competition in the national supply of an antidepressant medicine (Generics UK and IVAX/Norton Healthcare), 19 April 2013
Ravi S. Mehta - Blackstone Chambers (London)

The UK OFT issues a Statement of Objections to four pharma manufacturers for anticompetitive agreements over the supply of paroxetine (GSK, Alpharma, Generics UK and Norton Healthcare), 19 April 2013
Gabriele Accardo - Stanford Law School

The CMA is investigating a suspected breach of competition law in the pharmaceutical sector under Chapter II CA98 and Article 102 of TFEU.

Case timetable

Date	Action
August 2016 (estimate)	Decision on whether to proceed with the investigation or to close the investigation
March to July 2016 (estimate)	Initial investigation: information gathering, including issuance of formal or informal information requests and parties’ responses. CMA analysis and review of parties’ responses to information requests. Potential state of play meetings with parties under investigation
March 2016	Investigation opened

Notes

• The investigation is under Chapter II of the Competition Act 1998 (CA98) and Article 102 of the Treaty on the Functioning of the European Union (TFEU).
• The CMA has not reached a view as to whether there is sufficient evidence of an infringement of competition law for it to issue a statement of objections to the party/parties under investigation. Not all cases result in the CMA issuing a statement of objections. As a result, it would not be appropriate to include any further estimates of the timing of any later investigative steps at this stage.
• Changes to the timing of original entries in the case timetable will be made where the estimated timing changes.

Contacts

Assistant project director

Emma Ngoga (0203 738 6752, )

Project director

James MacBeth (0203 738 6958, )

Senior responsible officer

Andrew Groves (0203 738 6927, )

https://www.gov.uk/cma-cases/pharmaceutical-sector-anti-competitive-practices